Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 26, 2016 20:44:50 GMT -5
do we have Type 1 billionaireS?
Amylin came extremely close to going out of business in 1999, after Johnson & Johnson abruptly pulled out of a deal to develop Symlin. It received an emergency infusion of cash led by a software entrepreneur who thought the drug might be useful for his diabetic daughter.
|
|
|
|
Post by dreamboatcruise on Jan 26, 2016 20:49:05 GMT -5
Just a question- just throwing this out there- Would the potential / a potential lawsuit against SFY sweeten the deal here? If someone were to buy the company, would they still be able to go after SFY provided MNKD doesn't take some low ball offer from SFY. Just a thought. This could all still be speculation, but the SP is up.. I'd say it lessens the chance of getting big $$ from SNY. If they sell for a song, the company that would then sue would have actually benefited from SNY's bungling. If we sell for a lot then SNY can argue there wasn't much harm. If it is another big pharma they don't have to worry about a jury sympathizing with the underdog since it would then be two big dogs fighting. Of course if it does sell for a song, maybe that opens up chance for shareholder suit directly at SNY. I suggested a direct suit earlier and someone shot me down with some legal theory that I could not refute... but maybe if there is no MNKD still existing to sue on MNKD shareholders benefit, then we could as a class. (though I fully expect I'm wrong on that notion) |
|
|
|
Post by dreamboatcruise on Jan 26, 2016 20:56:24 GMT -5
"I doubt it would be $7.5 as someone above is wishing for." You only "doubt" it, dbc?  I'm playing nice You know people might block me otherwise. That would dredge up all sorts of memories of childhood rejection... and I'm sullen enough already. $7.5 would indeed be a welcome surprise... with a probability somewhere between having a good commute home and winning a billion in the lottery. |
|
|
|
Post by mnkdfann on Jan 26, 2016 21:02:20 GMT -5
|
|
|
|
Post by 4allthemarbles on Jan 26, 2016 21:22:23 GMT -5
Just a question- just throwing this out there- Would the potential / a potential lawsuit against SFY sweeten the deal here? If someone were to buy the company, would they still be able to go after SFY provided MNKD doesn't take some low ball offer from SFY. Just a thought. This could all still be speculation, but the SP is up.. simple answer, 4allthemarbles, NO! We're all gonna have to settle for a lot less than all the marbles here. You have been waiting years for an opportunity to use that line. Years. |
|
|
|
Post by jurystillout on Jan 26, 2016 21:23:21 GMT -5
Could also mean mnkd will sell technosphere to Receptor life science and use the proceeds to fund Affreza, or then again it may be just rumor???
|
|
|
|
Post by dstevenson on Jan 26, 2016 22:17:36 GMT -5
No man you got it backwards. Afrezza is the step child they want to rid of, they'll either sell afrezza franchise or sell everything. They will not sell TS and be stuck with afrezza, that leaves them with absolutely nothing but 1 drug with no future products from it.
|
|
|
|
Post by bill on Jan 26, 2016 22:50:29 GMT -5
MNKD has one big problem; something around a $100m shortfall. If they had that extra cash today the share price would be 5 to 10 times higher because there would be little risk of BK before they righted the Afrezza ship and had TS partnerships generating cash.
Absent that cash, their situation is more difficult because they're not on a level playing field. They're outgunned by the shorts and hedge funds that are invested in all that short interest. If MNKD could solve that problem, the share price would ascend to something more reasonable and they could do a secondary to generate that $100m without massive dilution.
One way to work the second problem could be to explore a sale of Afrezza and/or MNKD. If substantial offers are made then the share price is likely to ascend making it practical to do that secondary to generate the cash that would make MNKD more valuable because it wouldn't be facing BK for an extended period of time. Even an open market sale of a few million shares would be helpful once the price recovered a bit.
Perhaps getting the word out that they're exploring a sale is at least being done it part to generate some pressure on the shorts and hedge funds. Turn about would be fair play!
|
|
|
|
Post by peppy on Jan 27, 2016 3:29:03 GMT -5
|
|
|
|
Post by waldemar on Jan 27, 2016 3:56:27 GMT -5
I see some people here expecting buyout price of pps $ 5 - 10 and more. In my opinion, currently, MNKD is not in a position to negotiate a good price as they are in a tough financial condition. SNY did their dirty deed to ruin the image of MNKD and Afrezza and to scare the investors (despite the excellent real world feedback). Possible buyers know this very well and when it comes to money they won't care about the personality of Al Mann, his previous deals, MNKD employees, shareholders, etc. The buyer will pay the LEAST possible amount. Even if there is a bidding I don't expect the highest offer now to be more than $ 2 - 2.5 per share.
MNKD need to ensure financing for at least 1.5 years, start marketing on their own at a reasonable and competitive price of Afrezza and show that the sales have huge potential even with small resources. This will lift the share price and they will be in a better position to negotiate.
Selling now means that management just want to get rid of the company and treat it as a burden. I hope this is not the truth...
|
|
|
|
Post by patten1962 on Jan 27, 2016 5:24:01 GMT -5
I personally am not expecting a buyout. Would be nice! I believe something is happening tho with after hours large buying! I am in athe a low price. Would not mind a little push back up in the low $2 range by the end of the week!
|
|
|
|
Post by mindovermatter on Jan 27, 2016 6:17:06 GMT -5
If Mannkind is seriously considering selling Afrezza or itself, I would think it would want to get a deal done prior to the April 4th hand over if possible.
|
|
|
|
Post by vestful on Jan 27, 2016 7:56:17 GMT -5
Exploring? Yes, Matt even said they are looking at all options. That doesn't mean they have to sell everything tomorrow or that they intend to sell. However, you would want to know where the interests and your possibilities stand. As a result it could lead to talks of smaller spinoff agreements once mnkd understands an interested parties intentions or targets while keeping the short side and opposition on their toes.
|
|
|
|
Post by hawaiiguy42 on Jan 27, 2016 7:58:25 GMT -5
I do not believe the Reuters article to be a rumor, see writers information below.
Carl O'Donnell joined Reuters this month as healthcare mergers and acquisitions reporter and latest addition to the Reuters Deal team.
Before Reuters, O’Donnell was a reporter for Mergermarket, where he covered real estate, gaming, lodging and M&A’s.
His most recent Reuters healthcare stories have covered Berskhire Partners LLC’s potential acquisition of Affordable Care, Inc., the largest U.S. denture provider and the merger between Dentsply International Inc and Sirona Dental Systems Inc, forming the world’s largest dental equipment maker.
O’Donnell is based in the greater Philadelphia area and prefers to be contacted directly via email at carl.odonnell@thomsonreuters.com.
|
|
|
|
Post by stevil on Jan 27, 2016 8:18:56 GMT -5
Correct. MNKD doesn't sell here if they feel like they can avoid bankruptcy. MNKD doesn't sell here if Al Mann is not happy with whatever offer he can get. My gut tells me he won't be happy at all, and therefore, no sale. Al didn't start MNKD to make money- he started it as a philanthropic effort. He was already a billionaire and publicly stated that he didn't want to leave his fortune to his children. He's not in this for the money, although he's not in it to lose money either. If they are entertaining any deals, it's not because they're trying to profit on the company. It's because they're being forced to sell out of inevitable bankruptcy. I don't know Al personally, so this comment might seem silly, but I can almost guarantee you that he wouldn't hand over this company to someone else unless he needed to. He'd much rather keep it in the hands of those whom he appointed and trusts. |
|
